Drugs / PSMA-UCAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06895811 | Mar 2025 → Jul 2026 overdue | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Shanghai Changzheng Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSMA-UCAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06895811 ↗ |
| Known as | BRL-302 | “PSMA-UCAR T (BRL-302)” NCT06895811 ↗ |
| Modality | Cell therapy | “PSMA-Universal Chimeric Antigen Receptor (UCAR) T-lymphocytes” NCT06895811 ↗ |